BlackRock Health Sciences Term Trust Announces Monthly Dividend of $0.11 (NYSE:BMEZ)

BlackRock Health Sciences Term Trust (NYSE:BMEZ) declared a monthly dividend on Thursday, September 10th. Investors of record on Friday, December 11th will be given a dividend of 0.11 per share on Tuesday, December 22nd. This represents a c) dividend on an annualized basis and a yield of 8.0%. The ex-dividend date of this dividend is Friday, December 11th.

BlackRock Health Sciences Term Trust Trading Down 1.2%

NYSE BMEZ opened at $16.54 on Friday. BlackRock Health Sciences Term Trust has a fifty-two week low of $13.70 and a fifty-two week high of $17.25. The stock has a 50-day simple moving average of $16.05 and a two-hundred day simple moving average of $14.99.

Institutional Investors Weigh In On BlackRock Health Sciences Term Trust

A number of institutional investors have recently modified their holdings of the business. Kestra Advisory Services LLC acquired a new stake in BlackRock Health Sciences Term Trust in the fourth quarter valued at approximately $26,000. SouthState Bank Corp purchased a new position in BlackRock Health Sciences Term Trust in the 1st quarter valued at about $29,000. PNC Financial Services Group Inc. acquired a new position in shares of BlackRock Health Sciences Term Trust during the first quarter valued at approximately $35,000. Geneos Wealth Management Inc. acquired a new stake in shares of BlackRock Health Sciences Term Trust in the first quarter worth approximately $40,000. Finally, Integrated Wealth Concepts LLC purchased a new position in BlackRock Health Sciences Term Trust in the 2nd quarter valued at $46,000.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.

The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services.